AbbVie Inc. Financials
AbbVie Inc. (ABBV) reported $61.2B in revenue for fiscal year 2025, up 8.6% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
AbbVie’s dominant mechanic is durable cash production supporting distributions while accounting earnings and equity deteriorate.
Revenue recovery did not restore earnings intensity: net margin was6.9% in FY2025, below8.9% in FY2023. Meanwhile, operating margin recovered to24.7% from16.2% in FY2024, indicating that operating improvement is being absorbed below operating income rather than reaching shareholders proportionally.
Operating cash flow of
The balance sheet is increasingly liability-funded: FY2025 liabilities of
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of AbbVie Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
AbbVie Inc. has an operating margin of 24.6%, meaning the company retains $25 of operating profit per $100 of revenue. This strong profitability earns a score of 85/100, reflecting efficient cost management and pricing power. This is up from 16.2% the prior year.
AbbVie Inc.'s revenue grew 8.6% year-over-year to $61.2B, a solid pace of expansion. This earns a growth score of 55/100.
AbbVie Inc.'s current ratio of 0.67 is below the typical benchmark, resulting in a score of 8/100. This tight liquidity could limit financial flexibility if cash inflows slow.
AbbVie Inc. converts 29.1% of revenue into free cash flow ($17.8B). This strong cash generation earns a score of 95/100.
AbbVie Inc. scores 2.56, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($462.9B) relative to total liabilities ($137.2B). This signals moderate financial risk that warrants monitoring.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
AbbVie Inc. passes 7 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, AbbVie Inc. generates $4.50 in operating cash flow ($19.0B OCF vs $4.2B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
AbbVie Inc. earns $5.21 in operating income for every $1 of interest expense ($15.1B vs $2.9B). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
AbbVie Inc. generated $61.2B in revenue in fiscal year 2025. This represents an increase of 8.6% from the prior year.
AbbVie Inc.'s EBITDA was $23.2B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 32.5% from the prior year.
AbbVie Inc. reported $4.2B in net income in fiscal year 2025. This represents a decrease of 1.2% from the prior year.
AbbVie Inc. earned $2.36 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 1.3% from the prior year.
Cash & Balance Sheet
AbbVie Inc. generated $17.8B in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 0.1% from the prior year.
AbbVie Inc. held $5.2B in cash against $58.9B in long-term debt as of fiscal year 2025.
AbbVie Inc. paid $6.65 per share in dividends in fiscal year 2025. This represents an increase of 5.7% from the prior year.
Margins & Returns
AbbVie Inc.'s gross margin was 70.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.3 percentage points from the prior year.
AbbVie Inc.'s operating margin was 24.6% in fiscal year 2025, reflecting core business profitability. This is up 8.4 percentage points from the prior year.
AbbVie Inc.'s net profit margin was 6.9% in fiscal year 2025, showing the share of revenue converted to profit. This is down 0.7 percentage points from the prior year.
Not reported for fiscal year 2025.
Capital Allocation
AbbVie Inc. invested $9.1B in research and development in fiscal year 2025. This represents a decrease of 28.9% from the prior year.
AbbVie Inc. spent $980.0M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 42.6% from the prior year.
AbbVie Inc. invested $1.2B in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 24.6% from the prior year.
ABBV Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $64.4B | $61.2B+8.6% | $56.3B+3.7% | $54.3B-6.4% | $58.1B+3.3% | $56.2B+22.7% | $45.8B+37.7% | $33.3B+1.6% | $32.8B+16.1% | $28.2B+10.1% | $25.6B+12.2% | $22.9B+14.5% | $20.0B+6.2% | $18.8B+2.2% | $18.4B+5.4% | $17.4B |
| Cost of Revenue | N/A | $18.2B+7.7% | $16.9B-17.2% | $20.4B+17.2% | $17.4B-0.2% | $17.4B+13.4% | $15.4B+106.8% | $7.4B-3.6% | $7.7B+9.6% | $7.0B+20.7% | $5.8B+29.6% | $4.5B+1.7% | $4.4B-3.4% | $4.6B+1.6% | $4.5B-2.8% | $4.6B |
| Gross Profit | $46.0B | $43.0B+8.9% | $39.4B+16.3% | $33.9B-16.6% | $40.6B+4.9% | $38.8B+27.4% | $30.4B+17.8% | $25.8B+3.2% | $25.0B+18.2% | $21.2B+6.9% | $19.8B+7.9% | $18.4B+18.2% | $15.5B+9.3% | $14.2B+2.4% | $13.9B+8.3% | $12.8B |
| R&D Expenses | N/A | $9.1B-28.9% | $12.8B+66.7% | $7.7B+17.9% | $6.5B-6.0% | $6.9B+8.5% | $6.4B-0.4% | $6.4B-38.0% | $10.3B+106.3% | $5.0B+14.2% | $4.4B+2.3% | $4.3B+30.0% | $3.3B+15.5% | $2.9B+2.8% | $2.8B+6.1% | $2.6B |
| SG&A Expenses | N/A | $14.0B-5.0% | $14.8B+14.6% | $12.9B-15.6% | $15.3B+23.6% | $12.3B+9.3% | $11.3B+62.8% | $6.9B-6.2% | $7.4B+17.5% | $6.3B+7.0% | $5.9B-7.9% | $6.4B-17.3% | $7.7B+44.3% | $5.4B+7.3% | $5.0B-15.4% | $5.9B |
| Operating Income | N/A | $15.1B+65.0% | $9.1B-28.4% | $12.8B-29.6% | $18.1B+1.1% | $17.9B+57.7% | $11.4B-12.5% | $13.0B+103.4% | $6.4B-33.1% | $9.5B+2.2% | $9.3B+23.9% | $7.5B+121.0% | $3.4B-39.8% | $5.7B-2.6% | $5.8B+60.7% | $3.6B |
| Interest Expense | N/A | $2.9B+3.0% | $2.8B+26.3% | $2.2B-0.3% | $2.2B-8.0% | $2.4B-1.3% | $2.5B+37.6% | $1.8B+32.3% | $1.3B+17.2% | $1.1B+9.8% | $1.0B+45.6% | $719.0M+67.6% | $429.0M+43.5% | $299.0M+187.5% | $104.0M | N/A |
| Income Tax | N/A | $2.4B+514.7% | -$570.0M-141.4% | $1.4B-15.6% | $1.6B+13.3% | $1.4B+217.6% | -$1.2B-325.0% | $544.0M+211.0% | -$490.0M-120.3% | $2.4B+25.2% | $1.9B+28.6% | $1.5B+152.3% | $595.0M-50.6% | $1.2B+167.6% | $450.0M+91.5% | $235.0M |
| Net Income | $6.3B | $4.2B-1.2% | $4.3B-12.0% | $4.9B-58.9% | $11.8B+2.5% | $11.5B+150.0% | $4.6B-41.4% | $7.9B+38.6% | $5.7B+7.1% | $5.3B-10.8% | $6.0B+15.7% | $5.1B+190.0% | $1.8B-57.0% | $4.1B-21.7% | $5.3B+53.7% | $3.4B |
| EPS (Diluted) | $3.54 | $2.36-1.3% | $2.39-12.1% | $2.72-59.0% | $6.63+2.8% | $6.45+137.1% | $2.72-48.5% | $5.28+44.3% | $3.66+10.9% | $3.30-9.1% | $3.63+16.0% | $3.13+184.5% | $1.10-57.0% | $2.56-23.6% | $3.35+53.7% | $2.18 |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
ABBV Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $134.0B-0.9% | $135.2B+0.3% | $134.7B-2.9% | $138.8B-5.3% | $146.5B-2.7% | $150.6B+69.0% | $89.1B+50.1% | $59.4B-16.2% | $70.8B+7.1% | $66.1B+24.6% | $53.0B+92.8% | $27.5B-5.8% | $29.2B+8.1% | $27.0B | N/A |
| Current Assets | $29.1B+13.6% | $25.6B-22.5% | $33.0B+15.9% | $28.5B+1.9% | $27.9B+15.5% | $24.2B-51.2% | $49.5B+192.2% | $16.9B-20.2% | $21.2B+31.1% | $16.2B-0.8% | $16.3B+1.4% | $16.1B-9.9% | $17.8B+16.2% | $15.4B | N/A |
| Cash & Equivalents | $5.2B-5.3% | $5.5B-56.9% | $12.8B+39.3% | $9.2B-5.6% | $9.7B+15.4% | $8.4B-78.8% | $39.9B+447.7% | $7.3B-21.6% | $9.3B+82.4% | $5.1B-39.3% | $8.4B+0.6% | $8.3B-13.0% | $9.6B+62.6% | $5.9B+21755.6% | $27.0M |
| Inventory | $5.0B+18.4% | $4.2B+2.0% | $4.1B+14.5% | $3.6B+14.4% | $3.1B-5.5% | $3.3B+82.6% | $1.8B+13.0% | $1.6B0.0% | $1.6B+11.1% | $1.4B-16.0% | $1.7B+52.9% | $1.1B-2.3% | $1.1B+5.4% | $1.1B | N/A |
| Accounts Receivable | $12.6B+15.3% | $10.9B-2.1% | $11.2B-0.9% | $11.3B+12.8% | $10.0B+13.1% | $8.8B+62.5% | $5.4B+0.8% | $5.4B+5.8% | $5.1B+6.9% | $4.8B+0.6% | $4.7B | N/A | N/A | N/A | N/A |
| Goodwill | $35.6B+2.0% | $35.0B+8.2% | $32.3B+0.4% | $32.2B-0.7% | $32.4B-2.2% | $33.1B+112.3% | $15.6B-0.4% | $15.7B-0.8% | $15.8B+2.4% | $15.4B+17.1% | $13.2B+124.6% | $5.9B-6.6% | $6.3B+2.4% | $6.1B+0.5% | $6.1B |
| Total Liabilities | $137.2B+4.1% | $131.8B+6.0% | $124.4B+2.3% | $121.6B-7.3% | $131.1B-4.6% | $137.5B+41.3% | $97.3B+43.5% | $67.8B+3.2% | $65.7B+6.9% | $61.5B+25.2% | $49.1B+90.5% | $25.8B+4.3% | $24.7B-9.7% | $27.4B | N/A |
| Current Liabilities | $43.3B+11.7% | $38.7B+2.4% | $37.8B+28.1% | $29.5B-16.1% | $35.2B+22.8% | $28.7B+83.9% | $15.6B-9.6% | $17.2B+3.6% | $16.6B+70.1% | $9.8B-10.2% | $10.9B-4.4% | $11.4B+65.6% | $6.9B+1.5% | $6.8B | N/A |
| Long-Term Debt | $58.9B-2.3% | $60.3B+15.6% | $52.2B-11.7% | $59.1B-7.9% | $64.2B-17.2% | $77.6B+23.2% | $63.0B+79.9% | $35.0B+13.1% | $31.0B-15.1% | $36.4B+24.6% | $29.2B+177.5% | $10.5B-26.3% | $14.3B-2.3% | $14.6B | N/A |
| Total Equity | -$3.3B-198.3% | $3.3B-67.9% | $10.4B-40.0% | $17.3B+12.0% | $15.4B+17.8% | $13.1B+260.0% | -$8.2B+3.2% | -$8.4B-265.7% | $5.1B+9.9% | $4.6B+17.5% | $3.9B+126.5% | $1.7B-61.2% | $4.5B+1383.4% | -$350.0M | N/A |
| Retained Earnings | -$15.5B-96.1% | -$7.9B-690.0% | -$1.0B-120.9% | $4.8B+53.0% | $3.1B+196.4% | $1.1B-77.6% | $4.7B+40.1% | $3.4B-38.3% | $5.5B+24.7% | $4.4B+94.8% | $2.2B+320.2% | $535.0M-65.9% | $1.6B | N/A | N/A |
ABBV Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $19.5B | $19.0B+1.2% | $18.8B-17.7% | $22.8B-8.4% | $24.9B+9.5% | $22.8B+29.5% | $17.6B+32.0% | $13.3B-0.8% | $13.4B+34.8% | $10.0B+41.5% | $7.0B-6.6% | $7.5B+112.3% | $3.5B-43.4% | $6.3B-1.2% | $6.3B+1.6% | $6.2B |
| Capital Expenditures | $1.3B | $1.2B+24.6% | $974.0M+25.4% | $777.0M+11.8% | $695.0M-11.7% | $787.0M-1.4% | $798.0M+44.6% | $552.0M-13.5% | $638.0M+20.6% | $529.0M+10.4% | $479.0M-10.0% | $532.0M-13.1% | $612.0M+24.6% | $491.0M+47.4% | $333.0M-6.5% | $356.0M |
| Free Cash Flow | $18.2B | $17.8B-0.1% | $17.8B-19.2% | $22.1B-9.0% | $24.2B+10.3% | $22.0B+31.0% | $16.8B+31.5% | $12.8B-0.1% | $12.8B+35.6% | $9.4B+43.7% | $6.6B-6.3% | $7.0B+138.4% | $2.9B-49.2% | $5.8B-3.9% | $6.0B+2.1% | $5.9B |
| Investing Cash Flow | -$6.5B | -$6.6B+68.1% | -$20.8B-936.3% | -$2.0B-222.5% | -$623.0M+73.4% | -$2.3B+93.8% | -$37.6B-6401.5% | $596.0M+159.2% | -$1.0B-267.2% | -$274.0M | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | -$12.9B | -$12.7B-144.2% | -$5.2B+69.7% | -$17.2B+30.6% | -$24.8B-30.3% | -$19.0B-65.5% | -$11.5B-161.5% | $18.7B+230.0% | -$14.4B-161.2% | -$5.5B-40.3% | -$3.9B | N/A | N/A | N/A | N/A | N/A |
| Dividends Paid | $12.0B | $11.7B+5.7% | $11.0B+4.6% | $10.5B+4.9% | $10.0B+8.4% | $9.3B+20.0% | $7.7B+21.2% | $6.4B+14.1% | $5.6B+35.9% | $4.1B+10.5% | $3.7B+12.8% | $3.3B+23.8% | $2.7B+4.1% | $2.6B | N/A | N/A |
| Share Buybacks | $1.5B | $980.0M-42.6% | $1.7B-13.4% | $2.0B+32.6% | $1.5B+59.2% | $934.0M-4.5% | $978.0M+55.5% | $629.0M-94.8% | $12.0B+752.1% | $1.4B-76.6% | $6.0B-20.5% | $7.6B+1040.8% | $665.0M+107.8% | $320.0M | N/A | N/A |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
ABBV Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 70.2%+0.3pp | 70.0%+7.6pp | 62.4%-7.6pp | 70.0%+1.0pp | 69.0%+2.5pp | 66.4%-11.2pp | 77.6%+1.2pp | 76.4%+1.4pp | 75.0%-2.2pp | 77.3%-3.1pp | 80.3%+2.5pp | 77.8%+2.2pp | 75.6%+0.1pp | 75.5%+2.1pp | 73.4% |
| Operating Margin | 24.6%+8.4pp | 16.2%-7.3pp | 23.5%-7.7pp | 31.2%-0.7pp | 31.9%+7.1pp | 24.8%-14.2pp | 39.0%+19.5pp | 19.5%-14.3pp | 33.8%-2.6pp | 36.4%+3.5pp | 33.0%+15.9pp | 17.1%-13.1pp | 30.1%-1.5pp | 31.6%+10.9pp | 20.8% |
| Net Margin | 6.9%-0.7pp | 7.6%-1.4pp | 8.9%-11.4pp | 20.4%-0.2pp | 20.5%+10.5pp | 10.1%-13.6pp | 23.7%+6.3pp | 17.4%-1.5pp | 18.8%-4.4pp | 23.2%+0.7pp | 22.5%+13.6pp | 8.9%-13.1pp | 22.0%-6.7pp | 28.7%+9.0pp | 19.7% |
| Return on Equity | N/A | 128.7%+81.7pp | 46.9%-21.7pp | 68.6%-6.3pp | 74.9%+39.6pp | 35.3% | N/A | N/A | 104.2%-24.2pp | 128.4%-2.0pp | 130.4%+28.6pp | 101.8%+9.9pp | 91.9% | N/A | N/A |
| Return on Assets | 3.1%0.0pp | 3.2%-0.4pp | 3.6%-4.9pp | 8.5%+0.7pp | 7.9%+4.8pp | 3.1%-5.8pp | 8.8%-0.7pp | 9.6%+2.1pp | 7.5%-1.5pp | 9.0%-0.7pp | 9.7%+3.3pp | 6.5%-7.7pp | 14.1%-5.4pp | 19.5% | N/A |
| Current Ratio | 0.670.0x | 0.66-0.2x | 0.87-0.1x | 0.96+0.2x | 0.790.0x | 0.84-2.3x | 3.18+2.2x | 0.98-0.3x | 1.28-0.4x | 1.65+0.2x | 1.50+0.1x | 1.41-1.2x | 2.59+0.3x | 2.27 | N/A |
| Debt-to-Equity | N/A | 18.15+13.1x | 5.04+1.6x | 3.43-0.7x | 4.17-1.8x | 5.93 | N/A | N/A | 6.07-1.8x | 7.86+0.4x | 7.41+1.4x | 6.05+2.9x | 3.18 | N/A | N/A |
| FCF Margin | 29.1%-2.5pp | 31.6%-9.0pp | 40.6%-1.2pp | 41.8%+2.6pp | 39.1%+2.5pp | 36.7%-1.7pp | 38.4%-0.7pp | 39.1%+5.6pp | 33.4%+7.8pp | 25.6%-5.0pp | 30.6%+15.9pp | 14.7%-16.0pp | 30.7%-2.0pp | 32.7%-1.1pp | 33.8% |
Note: Shareholder equity is negative (-$3.3B), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.67), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Where AbbVie Inc. Ranks
Frequently Asked Questions
What is AbbVie Inc.'s annual revenue?
AbbVie Inc. (ABBV) reported $61.2B in total revenue for fiscal year 2025. This represents a 8.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is AbbVie Inc.'s revenue growing?
AbbVie Inc. (ABBV) revenue grew by 8.6% year-over-year, from $56.3B to $61.2B in fiscal year 2025.
Is AbbVie Inc. profitable?
Yes, AbbVie Inc. (ABBV) reported a net income of $4.2B in fiscal year 2025, with a net profit margin of 6.9%.
What is AbbVie Inc.'s EBITDA?
AbbVie Inc. (ABBV) had EBITDA of $23.2B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does AbbVie Inc. have?
As of fiscal year 2025, AbbVie Inc. (ABBV) had $5.2B in cash and equivalents against $58.9B in long-term debt.
What is AbbVie Inc.'s gross margin?
AbbVie Inc. (ABBV) had a gross margin of 70.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is AbbVie Inc.'s operating margin?
AbbVie Inc. (ABBV) had an operating margin of 24.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is AbbVie Inc.'s net profit margin?
AbbVie Inc. (ABBV) had a net profit margin of 6.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
Does AbbVie Inc. pay dividends?
Yes, AbbVie Inc. (ABBV) paid $6.65 per share in dividends during fiscal year 2025.
What is AbbVie Inc.'s free cash flow?
AbbVie Inc. (ABBV) generated $17.8B in free cash flow during fiscal year 2025. This represents a -0.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is AbbVie Inc.'s operating cash flow?
AbbVie Inc. (ABBV) generated $19.0B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are AbbVie Inc.'s total assets?
AbbVie Inc. (ABBV) had $134.0B in total assets as of fiscal year 2025, including both current and long-term assets.
What are AbbVie Inc.'s capital expenditures?
AbbVie Inc. (ABBV) invested $1.2B in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does AbbVie Inc. spend on research and development?
AbbVie Inc. (ABBV) invested $9.1B in research and development during fiscal year 2025.
What is AbbVie Inc.'s current ratio?
AbbVie Inc. (ABBV) had a current ratio of 0.67 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is AbbVie Inc.'s return on assets (ROA)?
AbbVie Inc. (ABBV) had a return on assets of 3.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Why is AbbVie Inc.'s debt-to-equity ratio negative or not reported?
AbbVie Inc. (ABBV) has negative shareholder equity of -$3.3B as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is AbbVie Inc.'s Altman Z-Score?
AbbVie Inc. (ABBV) has an Altman Z-Score of 2.56, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is AbbVie Inc.'s Piotroski F-Score?
AbbVie Inc. (ABBV) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are AbbVie Inc.'s earnings high quality?
AbbVie Inc. (ABBV) has an earnings quality ratio of 4.50x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can AbbVie Inc. cover its interest payments?
AbbVie Inc. (ABBV) has an interest coverage ratio of 5.21x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is AbbVie Inc.?
AbbVie Inc. (ABBV) scores 58 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.